Suspended

UVB Excimer Light for Hair Regrowth in Alopecia Areata

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

UVB excimer light

Procedure
Who is being recruted

Alopecia+3

+ Hair Diseases

+ Hypotrichosis

Over 19 Years
+9 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
Study Start: February 2013
See protocol details

Summary

Principal SponsorUniversity of British Columbia
Study ContactHarvey Lui, MD, FRCPCMore contacts
Last updated: July 2, 2015
Sourced from a government-validated database.Claim as a partner

Study start date: February 1, 2013

Actual date on which the first participant was enrolled.

Alopecia Areata (AA) is a chronic autoimmune inflammatory disease causing nonscarring hair loss. Many treatment modalities have been found to be helpful in AA, however, none on them cure the disease. Excimer laser has been shown to be effective in the treatment of AA in controlled studies. The main disadvantage of the previous studies evaluating excimer laser is choosing separate patches as a control which does not account for interlesional treatment response variability. UVB excimer light has recently emerged as a new therapeutic modality in many dermatologic diseases. However, there are only a few studies that evaluated the efficacy and safety of UVB excimer light in AA. Those studies have shown that UVB excimer light is effective in the treatment of AA but none of them was conducted in a controlled fashion. There are no prospective randomized controlled trials evaluating the efficacy and safety of UVB excimer light in AA. We plan on conducting a prospective split lesion single-blinded randomized clinical trial to assess efficacy and safety of UVB excimer light in the treatment of AA. Study Objectives To evaluate the potential for UVB excimer light to induce hair regrowth within AA patches. To assess the side effect profile of UVB excimer light when used in the treatment of AA.

Principal SponsorUniversity of British Columbia
Study ContactHarvey Lui, MD, FRCPCMore contacts
Last updated: July 2, 2015
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

18 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 19 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

AlopeciaHair DiseasesHypotrichosisSkin DiseasesSkin and Connective Tissue DiseasesAlopecia Areata

Criteria

3 inclusion criteria required to participate
Age > 18 years

Subject has a patch of at least 12 cm2 on the scalp with no evidence of hair regrowth

Subject is willing and capable of cooperating to the extent and degree required by the protocol

6 exclusion criteria prevent from participating
History of previous skin cancer

Patients that have participated in another investigational drug or device study within 30 days of enrollment

Patients who received treatment for alopecia areata within the past 4 weeks

Patients with alopecia totalis or alopecia universalis

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Patches of alopecia will be treated twice weekly with UVB excimer light. Only one half of a single alopecia areata patch will be treated. In order to treat the same half during each visit, a transparent sheet will be marked, using a marking pen, to delineate the borders of the treatment area with a central dividing line. The other half will be covered and used as a control. Treatments will be given randomly (by sealed envelope randomization method) into one of the two halves in different patients but will be given into the same half in each patient in all treatment sessions. Only one investigator will know the intervention each half has received. A total of 23 treatments will be given over 12 weeks.

Group II

No Intervention

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

The Skin Care Center, Vancouver General Hospital

Vancouver, CanadaOpen The Skin Care Center, Vancouver General Hospital in Google Maps
SuspendedOne Study Center